It was reported that the patient developed redness, hardness, and warmth at the site of rituximab administration that led to significant expansive bruising four to five days after the treatment.The rituximab 1400mg was administered subcutaneously in the abdominal area using saf-t-intima iv catheter through syringe pump over 5 minutes.The pump was programmed used guardrails drug library.Due to the symptoms, patient was given cephalexin (keflex) oral antibiotic.Furthermore, it was mentioned that subcutaneous rituximab has been previously given through slow syringe administration.The facility recently changed their practice and began using syringe pumps.There were no reported incidents prior to use of pumps and since the events, the clinicians reverted back to previous practice.
|